

# Butyrate modulates bacterial adherence on LS174T human colorectal cells by stimulating mucin secretion and MAPK signaling pathway

Tae-Hwan Jung<sup>1</sup>, Jeong Hyeon Park<sup>2</sup>, Woo-Min Jeon<sup>1S</sup> and Kyoung-Sik Han<sup>1</sup>

<sup>1</sup>Department of Animal Biotechnology and Resource, Sahmyook University, Hwarangro 815, Nowon-gu, Seoul 139-742, Korea

<sup>2</sup>Institute of Fundamental Sciences, Massey University, Private Bag 11 222, Palmerston North, New Zealand

**BACKGROUND/OBJECTIVES:** Fermentation of dietary fiber results in production of various short chain fatty acids in the colon. In particular, butyrate is reported to regulate the physical and functional integrity of the normal colonic mucosa by altering mucin gene expression or the number of goblet cells. The objective of this study was to investigate whether butyrate modulates mucin secretion in LS174T human colorectal cells, thereby influencing the adhesion of probiotics such as *Lactobacillus* and *Bifidobacterium* strains and subsequently inhibiting pathogenic bacteria such as *E. coli*. In addition, possible signaling pathways involved in mucin gene regulation induced by butyrate treatment were also investigated.

**MATERIALS/METHODS:** Mucin protein content assay and periodic acid-Schiff (PAS) staining were performed in LS174T cells treated with butyrate at various concentrations. Effects of butyrate on the ability of probiotics to adhere to LS174T cells and their competition with *E. coli* strains were examined. Real time polymerase chain reaction for mucin gene expression and Taqman array 96-well fast plate-based pathway analysis were performed on butyrate-treated LS174T cells.

**RESULTS:** Treatment with butyrate resulted in a dose-dependent increase in mucin protein contents in LS174T cells with peak effects at 6 or 9 mM, which was further confirmed by PAS staining. Increase in mucin protein contents resulted in elevated adherence of probiotics, which subsequently reduced the adherent ability of *E. coli*. Treatment with butyrate also increased transcriptional levels of *MUC3*, *MUC4*, and *MUC12*, which was accompanied by higher gene expressions of signaling kinases and transcription factors involved in mitogen-activated protein kinase (MAPK) signaling pathways.

**CONCLUSIONS:** Based on our results, butyrate is an effective regulator of modulation of mucin protein production at the transcriptional and translational levels, resulting in changes in the adherence of gut microflora. Butyrate potentially stimulates the MAPK signaling pathway in intestinal cells, which is positively correlated with gut defense.

Nutrition Research and Practice 2015;9(4):343-349; doi:10.4162/nrp.2015.9.4.343; pISSN 1976-1457 eISSN 2005-6168

**Keywords:** Butyrate, LS174T cell, mucin protein, *MUC* gene, MAPK

## INTRODUCTION

Fermentation of dietary fiber by the colonic microflora results in production of various short chain fatty acids (SCFA), mainly acetate, propionate, and butyrate, which contribute to normal large bowel function and prevent pathology [1]. In particular, butyrate is reported to be a major regulator of homeostasis of the normal colonic mucosa by regulation of cell proliferation and differentiation for maintenance of physical and functional integrity [2-5].

Butyrate is a well-known inhibitor of histone deacetylase with anti-carcinogenic activity. Butyrate was also shown to activate three major mitogen-activated protein kinase (MAPK) signaling pathways [6-9]. Therefore, butyrate treatment could induce both pro- and anti-growth effects depending on the cell lines and experimental conditions.

The mucus layer is composed of a complex mixture containing

large amounts of mucin, a high molecular weight glycoprotein, which is considered the first line of defense against noxious substances and pathogens, and participates indirectly in the immune response [10,11]. Among different mucins, the oligosaccharide chains of mucin vary in both length and antigenic structure [12].

In the colonic mucosa, the main mucin gene is *MUC2*, a secretory mucin, and to a lesser extent *MUC1*, *MUC3*, and *MUC4*, which are both transmembrane mucins and secretory mucins from the splicing variants [13,14]. Apart from their distinct protective functions, some membrane-located mucins such as *MUC1* and *MUC4* possess adhesion and cell signaling properties.

The microbial community in the colon is considered important for the maintenance of gut health; dominant anaerobes such as lactobacilli and bifidobacteria confer numerous benefits to the host. However, beneficial bacteria must survive in the gastrointestinal tract (GIT) in order to establish functional microbe-

This paper was supported by Sahmyook University Research Fund in 2013.

<sup>S</sup> Corresponding Author: Woo-Min Jeon, Tel. 82-2-3399-1752, Fax. 82-2-3399-1762, Email. jeonwm@syu.ac.kr

Received: March 31, 2015, Revised: April 21, 2015, Accepted: May 18, 2015

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0/>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

host interactions [15]. Components of the gastrointestinal mucus could be substrates or adhesion factors for gut microbiota. Therefore, ability of bacteria to adhere to the host mucus layer is the most crucial attribute to perpetuation of colonization [16,17].

The importance of the mucin-expressing epithelium layer in the GIT has been well established, particularly in the area of innate immunity and protective antibacterial barrier formation [18-20]. However, the molecular mechanism of how SCFA affects the intestinal cellular response is not well understood.

Therefore, the objective of this study was to investigate whether butyrate modulates mucin secretion in LS174T human colorectal cells, thereby influencing adhesion of probiotics such as lactobacilli and bifidobacteria, and subsequently inhibiting pathogenic bacteria such as *E. coli*. In addition, possible signaling pathways involved in butyrate-dependent mucin gene expression were also investigated using real time polymerase chain reaction (PCR) assays.

## MATERIALS AND METHODS

### *Cell culture and butyrate treatment*

The LS174T human colorectal cancer cell line was purchased from the Korean Cell Line Bank (Seoul, Korea). All media and reagents were purchased from Life Technologies (Thermo Fisher Scientific Inc., MA, USA). Cells were grown in Minimum Essential Medium Eagle (MEM) supplemented with 10% fetal bovine serum, 1% non-essential amino acids, penicillin (100 U/ml), and streptomycin (100 U/ml) at 37°C with 5% CO<sub>2</sub> in a humidified atmosphere. Confluent cells were subcultured every 3-4 days by treatment with trypsin-EDTA solution. For mucin protein assay, periodic acid-Schiff (PAS) staining and bacterial adherence assay, LS174T cells ( $4 \times 10^6$  cells in 4 mL) were cultured in a 6-well plate (Nunc, USA) overnight, followed by addition of 100  $\mu$ L of sodium butyrate in MEM media or only MEM media to cultures as a control at final concentrations of 0, 3, 6, and 9 mM in triplicate. Cells were cultured for an additional 2 days. For RNA extraction, LS174T cells ( $1 \times 10^5$  cells in 1 mL) were cultured in a 24-well plate (Nunc, USA) overnight, followed by addition of 50  $\mu$ L of sodium butyrate solution to the cultures at a final concentration of 6 mM in triplicate. As a control, 50  $\mu$ L of MEM media was added to the cultures instead of sodium butyrate solution. Cells were then cultured for an additional 2 days.

### *Bacterial strains and culture condition*

The bacterial strains used in this study were obtained from the Korean Culture Center of Microorganisms (Seoul, Korea). *Lactobacillus acidophilus* ATCC 4356 were grown in MRS broth (BD Difco) at 37°C for 18 hours, *Bifidobacterium longum* ATCC 15707 were grown in reinforced clostridial medium (RCM, Oxoid) and *Escherichia coli* ATCC 43896 were grown in tryptic soy broth (BD Difco). Prior to the experiments, all bacteria were subcultured at least three times. For long-term storage, the stock culture was stored at -80°C in fresh broth containing 20% glycerol.

### *Mucin protein assay*

Butyrate-treated and control cells were collected in 1.5 mL

of phosphate-buffered saline (PBS) and then sonicated using a sonicator (Branson 8150, USA). After centrifugation at 12,000 rpm for 10 min, mucin protein in the supernatant was measured using an enzyme-linked immunosorbent assay kit (USCN Life Science Inc., USA) according to the manufacturer's instructions. Briefly, various dilutions of standards and samples were added to a pre-coated, ready-to-use 96-well strip plate and incubated for 2 hours at 37°C. After removal of the liquid from each well, 100  $\mu$ L of detection reagent A was added, followed by incubation for 1 hour at 37°C. The plate was washed four times with wash solution, followed by addition of 100  $\mu$ L of detection reagent B to each well, and incubation for 30 min at 37°C, and then washed four times. Then, 90  $\mu$ L of TMB substrate solution was added to each well, followed by incubation for 10-15 min at 37°C, and addition of 50  $\mu$ L of stop solution; the absorbance was read at 450 nm using an EMax microplate reader (Molecular devices, USA).

### *Periodic acid-Schiff staining*

Cell staining was performed using a PAS stain kit (ScyTek Laboratories Inc., USA) according to the manufacturer's guidelines. Briefly, cells were immersed in periodic acid solution for 5 min and rinsed four times with distilled water. Cells were immersed in Schiff's solution for 5 min, in Hematoxylin & Mayer's for 1 min, and then in Bluing reagent for 10 sec. Cells were washed four times after each step. Cells were then visualized using a microscope (Olympus BX51, Japan).

### *Bacterial adherence assay*

*Lactobacillus acidophilus* ATCC 4356 or *B. longum* ATCC 15707 ( $5 \times 10^7$  cfu per well) were added to butyrate-treated LS174T cells at final concentrations of 0, 3, 6, and 9 mM, respectively, followed by incubation for 5 hours at 37°C. For removal of non-bound bacteria, the plate was washed three times with PBS at 200 rpm for 3 min using a shaker (Heidoph Instruments, Germany). Serial dilutions of adherent bacteria were plated on MRS agar or RCM agar for subsequent CFU quantification. For analysis of the inhibitory effect of *L. acidophilus* or *B. longum* on adherence of *E. coli* ATCC 43896 to LS174T cells, butyrate-treated cells were incubated with *L. acidophilus* or *B. longum* for 5 hours and washed three times with PBS, followed by addition of *E. coli* ATCC 43896 at  $5 \times 10^7$  cfu per well and then incubation for an additional 5 hours. The plate was washed three times with PBS at 200 rpm for 3 min for removal of non-bound *E. coli*. Adherent *E. coli* were counted on MacConkey agar (BD difco) using the standard plate count method. All experiments were run in triplicate and results are based on three separate experiments.

### *Total RNA extraction and real time polymerase chain reaction*

The experiments were performed with modification of methods described by Han *et al.* [11]. Total RNA was extracted from cells using Trizol reagent and a PureLink RNA mini kit (Ambion, Life Technologies, USA) according to the manufacturer's guidelines. The first strand of cDNA was synthesized using a High capacity RNA-to-cDNA kit (Applied Biosystems, Thermo Fisher Scientific Inc., MA, USA). One microgram of total RNA, 1  $\mu$ L of 20X RT enzyme mix, 10  $\mu$ L of 2X RT buffer, and nuclease-free H<sub>2</sub>O were

added to yield a final volume of 20  $\mu$ L. The reaction mixture was then incubated at 37°C for 60 min and at 95°C for 5 min.

For real time PCR, all kits were purchased from Life Technology (Thermo Fisher Scientific Inc., MA, USA). The synthesized cDNA was diluted (1:3) with RNA-free water. Real time PCR was performed using the StepOnePlus™ Real-Time PCR system with Taqman Real-Time PCR master mix. Taqman gene expression assays were used as primers and probes for mucin genes (*MUC2*, *MUC3*, *MUC4*, and *MUC12*) along with an internal reference, *GAPDH*. Their catalog numbers were HS03005092\_m1, HS03649367\_mH, HS00366414\_m1, HS00419779\_m1, and HS99999905\_m1, respectively. The reaction mixture contained 4  $\mu$ L of diluted cDNA, 1  $\mu$ L of Taqman gene expression assays, 5  $\mu$ L of DNase-free water and 10  $\mu$ L of Taqman Real-Time PCR master mix in a final volume of 20  $\mu$ L. The cycling conditions of PCR were as follows: preincubation at 50°C for 2 min and then at 95°C for 10 min, followed by 45 amplification cycles (95°C, 15 s and 60°C, 1 min) and cooling (40°C, 10 s). For real time monitoring, the fluorescence was measured at the end of the elongation phase.

The pathway of gene expression induced by butyrate treatment was examined by application of synthesized cDNA to a TaqMan® array 96-well fast plate (Hs MAP Kinase). The reaction mixture contained 4  $\mu$ L of diluted cDNA, 1  $\mu$ L of DNase-free water, and 5  $\mu$ L of Taqman master mix. The cycling conditions of PCR were the same as described above. The comparative Ct method was used for relative quantification. The delta Ct value was determined by subtracting the average *GAPDH* Ct value from the individual Ct value of the target gene. The delta delta Ct value was determined by subtracting the delta Ct of the control sample from the individual delta Ct of the test sample. The fold change of the test sample relative to the control sample was determined by  $2^{-\text{delta delta Ct}}$ . Significant changes in butyrate-induced gene expression were analyzed based on more than 5-fold changes compared to the control.

#### Statistical analysis


Data are given as mean  $\pm$  SEM. Analysis of mucin protein and bacterial adhesion across treatments was performed using ANOVA (GLM procedures of SAS, SAS Institute, Cary, NC). Duncan's multiple range test was used for comparison of means. The SAS/PROC t-test was used for analysis of mucin gene expression. Statistical significance was accepted at  $P < 0.05$ .

## RESULTS

#### Mucin production and PAS staining

The effect of butyrate treatment on mucin protein production is shown in Fig. 1A. Cells treated with butyrate at 6 or 9 mM produced significantly ( $P < 0.05$ ) higher mucin protein content of more than 2.5-fold compared to the control (0 mM) or cells treated with 3 mM butyrate.

Polysaccharides of mucin glycoproteins were identified based on their red coloration by conventional PAS staining (Fig. 1B). Similar to mucin protein levels, treatment with butyrate resulted in a dose-dependent increase in the number of PAS-positive cells. A clearly visible increase in the cell population with higher mucin production was observed after treatment with butyrate at 6 or 9 mM, to a lesser extent at 3 mM.



**Fig. 1.** Effect of sodium butyrate treatment on mucin protein production in LS174T cells. (A) Cells were treated with sodium butyrate at final concentrations of 0, 3, 6 and 9 mM. Mucin protein contents were measured by enzyme-linked immunosorbent assay. Values are expressed as mean  $\pm$  SEM. Means without a common letter differ,  $P < 0.05$ . Con, control. (B) Periodic acid-Schiff staining of cells treated with sodium butyrate at final concentrations of 0 (I), 3 (II), 6 (III), and 9 mM (IV).


#### Bacterial adhesion

Adherence of *L. acidophilus* ATCC 4356 to LS174T cells treated with butyrate was measured at various concentrations (Fig. 2). Treatment with butyrate at 6 or 9 mM resulted in significantly ( $P < 0.01$ ) increased adherence of *L. acidophilus* compared to the control (0 mM) or 3 mM butyrate treatment. On the other hand, increased adherence of *L. acidophilus* by treatment with 6 mM butyrate resulted in significantly ( $P < 0.05$ ) reduced adherence of *E. coli* ATCC 43896, suggesting competition at the binding sites.


Similarly, treatment with butyrate at 6 or 9 mM resulted in significantly ( $P < 0.01$ ) increased adherence of *B. longum* ATCC 15707 compared to the control (Fig. 3). Increased adherence of *B. longum* by treatment with 6 or 9 mM butyrate resulted in significantly ( $P < 0.05$ ) decreased adherence of *E. coli* ATCC 43896 compared to the control or 3 mM butyrate treatment.

#### Mucin gene expression and pathway

The purified RNA samples from 6 mM butyrate-treated LS174T cells were converted into cDNAs, which were subjected to real time PCR for mucin gene expression and Taqman array 96-well fast plate-based pathway analysis. Butyrate-treated LS174T cells




**Fig. 2.** Adherence of *Lactobacillus acidophilus* ATCC 4356 to LS174T cells and its inhibitory effect on *Escherichia coli* ATCC 43896. LS174T cells were treated with sodium butyrate at final concentrations of 0, 3, 6, and 9 mM. Values are expressed as mean ± SEM, Means without a common letter differ,  $P < 0.01$  for *L. acidophilus* (black bar) and  $P < 0.05$  for *E. coli* (grey bar).



**Fig. 3.** Adherence of *Bifidobacterium longum* ATCC 15707 to LS174T cells and its inhibitory effect on *Escherichia coli* ATCC 43896. LS174T cells were treated with sodium butyrate at final concentrations of 0, 3, 6, and 9 mM. Values are expressed as mean ± SEM, Means without a common letter differ,  $P < 0.01$  for *B. longum* (black bar) and  $P < 0.05$  for *E. coli* (grey bar).

showed significantly ( $P < 0.05$ ) increased expression of *MUC3* and *MUC12* mRNA compared to the control (approximately 130 and 170% increase, respectively). In particular, *MUC4* mRNA expression showed a significant ( $P < 0.01$ ) increase of more than 17-fold compared to the control. However, butyrate treatment did not affect *MUC2* gene expression, suggesting a gene-specific




**Fig. 4.** Effect of 6 mM sodium butyrate treatment on mRNA expression levels of four mucin genes (*MUC2*, *MUC3*, *MUC4*, and *MUC12*) in LS174T cells. The mRNA expression of mucin genes was normalized to the GAPDH mRNA level in each sample. Real time PCR was performed in triplicate at each concentration. The results are expressed as percentage increases as compared to the control (0 mM). Graphs represent mean ± SEM of three separate experiments; \*  $P < 0.05$  and \*\*  $P < 0.01$  relative to control (CON) cells.

regulatory effect (Fig. 4).

As shown in Fig. 5, butyrate treatment induced significant changes in gene expression levels related to MAPK signaling intermediates and targets. Treatment with butyrate resulted in a significant increase of mRNA levels in key downstream kinases of MAPK and PI3/AKT signaling pathways, including *MNK2*, *PRAK*, *MSK1/2*, *p90RSK* and *p70RSK*. Consistent with higher expression levels of these kinases, key transcription factors in regulatory gene expression appeared to be upregulated. However, it remains to be determined whether higher mRNA levels of transcription factors could be directly translated to the higher protein levels of AP1, CREB, cMyc, NFκB and p53. Alterations due to activation of these transcription factors in colonic cells would contribute to cell proliferation survival, inflammation, and antitumor activity in the epithelial layer.

**DISCUSSION**

The total concentration of SCFA in the human large intestine is mainly derived from microbial fermentation of dietary carbohydrates and the molar proportion of three main SCFA (acetate, propionate, butyrate) appears to be dependent on different factors including composition of gut microbiota and



**Fig. 5.** Analysis of signaling pathways in 6 mM butyrate-treated LS174T cells. The synthesized cDNA was applied to a TaqMan array 96-well fast plate, and comparative Ct method for relative quantification was performed. The delta delta Ct value was determined by subtracting the delta Ct of the control sample from the individual delta Ct of the test sample. Significant changes in butyrate-induced gene expression were analyzed based on more than 5-fold changes compared to the control group. MAPKAPK, mitogen-activated protein kinase; P, protein

diet [21]. Acetate comprises approximately 60-75% of the total SCFA detected in human feces; however, due to their potentially beneficial effects on health, propionate and butyrate are of greater interest. In particular, butyrate, which is the major energy source for colonocytes, is implicated in prevention of colitis and colorectal cancer [22]. Butyrate, an inhibitor of histone-deacetylase, can modulate gene expression, signal transduction, and protein degradation pathways. Butyrate could also modulate mucin glycosylation by regulating the expression of certain enzymes involved in cellular glycosylation [5].

To date, the molecular mechanism of effects evoked by butyrate on colonic microbiota had not been well characterized; however, in this study, interaction between bacterial adherence and mucin secretion by treatment with butyrate was demonstrated. Cells rarely tolerate butyrate concentrations over 10 mM *In vitro*; therefore, concentration of butyrate below 10 mM were used. The preliminary cell viability tests confirmed that butyrate treatment below 10 mM did not significantly affect the cell growth (data not shown). The effect of butyrate on mucin protein content was clearly visible, whereas acetate and propionate had no effect.

So far, based on various *in vitro* and *in vivo* studies, butyrate appears to be the most effective SCFA in modulation of mucin production [13,23]. Butyrate has also been shown to increase mRNA expression levels of mucin in several cell lines derived from human colorectal cancers [24]. Dietary compounds including fiber and SCFA modulate the dynamics of mucus by altering the mucin gene expression or the numbers of goblet cells in the isolated vascularly perfused rat colon [25].

In this study, butyrate increased gene expression levels of *MUC3*, *MUC4*, and *MUC12* but not *MUC2* (Fig. 4). These results are in agreement with the findings of Gaudier *et al.* [13]. *MUC1*, *MUC3*, *MUC4*, and *MUC12* are members of the membrane-bound family of mucins. In particular, certain membrane-associated mucins such as *MUC1* and *MUC4* exhibit specific functions in bacterial adhesion [26].

Pathogenic *E. coli* strains cause food-borne illness, which is generally characterized by abdominal pain and diarrhea [27]. Endogenous secretions, such as mucin, may selectively provide diet-independent substrates for gut microbiota. Mucin might be a vital defense factor for removal of pathogens and support of commensal bacteria of the GIT [28]. Mack *et al.* [29] reported that probiotic *Lactobacillus* species can adhere to intestinal epithelial cells, and induce *MUC3* mucin expression. Subsequently, upregulated expression of the *MUC3* gene can inhibit adherence of enteric pathogen to epithelial cells. One possible mechanism involves competition of mucin binding sites between *E. coli* and *Lactobacillus* strains.

Probiotics are known to enhance human health and well-being, and their beneficial effects include competition for pathogen-binding and receptor sites in the gut [30]. Addition of mucin and probiotics, such as *L. casei* GG adhering to surface receptors of enterocytes, was reported to inhibit bacterial translocation of various pathogens in different *in vitro* models [31]. In this study, modulation of mucin secretion by butyrate treatment resulted in alteration of adherence of *Lactobacillus* or *Bifidobacterium* strains by providing favorable binding sites.

Ras, a small GTP-binding protein, plays a critical role in propa-

gation of extracellular signals from cell membrane receptors to downstream kinase cascades. Because it plays a pivotal role in cellular proliferation and survival, gain of activating mutations or amplification of the *ras* gene is commonly observed in one third of all human cancers [32,33]. Consistent with the critical role of Ras, significant upregulation of *k-ras* by butyrate treatment appears to stimulate all three MAPK pathways. As shown in Fig. 5, treatment with butyrate resulted in upregulated expression of most downstream kinase genes of MAPK signaling pathways, including *MNK1/2*, *RSK2*, *PRAK*, and *MSK1/2*. In addition, *ras* upregulation resulted in the activation of *p70S6K* expression through the PI3K/AKT cell survival pathway (data not shown). These downstream kinases are known to promote protein synthesis and cellular growth. Upregulated *MNK1/2*, *p70S6K*, and *RSK2* stimulate protein synthesis by modifying ribosomal proteins or translation initiation machinery [34, 35]. These kinases also indirectly stimulate cellular proliferation and survival by post-translational modification of key transcription factors such as Myc, CREB, c-Fos, and NF- $\kappa$ B. In addition to these modifications, results of our Taqman array 96-well fast plate analysis showed that butyrate treatment resulted in direct upregulation of the gene expression levels of these transcription factors, resulting in pro-cellular growth and cell survival [36-38]. p53 tumor suppressor is a genome guardian that protects normal cells from abnormal cellular growth and cancer development [39]. p53 protein is activated by oncogenic stress involving upregulation of *ras* or *myc* [40]. Given the hyperactive cellular growth signals induced by *ras* and *myc*, LS174 cells appear to undergo a protective cellular response through upregulation of the p53 tumor suppressor pathway. Consistent with upregulated p53, anti-cancer activity of butyrate was demonstrated in various studies [41,42]. Taken together, butyrate treatment would increase cell mass and promote cellular growth along with anti-tumor activity by altering gene expression levels of MAPK signaling intermediates and key transcription factors. This is in good agreement with reports of Hatayama *et al.* [24] and Perris *et al.* [43].

In conclusion, butyrate treatment increased mucin secretion through upregulation of the transcriptional and translational levels of mucin gene expression, which stimulates bacterial adherence to the mucus layer. The underlying molecular mechanism of enhanced mucin secretion by butyrate remains to be determined, however, the activation of MAPK signaling pathways is likely to play a role in the gene activation process. Our results will provide further molecular understanding of the contribution of butyrate to homeostasis of the normal colonic mucosa and epithelial cell health by modulation of bacterial adherence and MAPK signaling pathway.

## REFERENCES

1. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. *Physiol Rev* 2001;81:1031-64.
2. Shimotoyodome A, Meguro S, Hase T, Tokimitsu I, Sakata T. Short chain fatty acids but not lactate or succinate stimulate mucus release in the rat colon. *Comp Biochem Physiol A Mol Integr Physiol* 2000;125:525-31.

3. Blottière HM, Buecher B, Galmiche JP, Cherbut C. Molecular analysis of the effect of short-chain fatty acids on intestinal cell proliferation. *Proc Nutr Soc* 2003;62:101-6.
4. Young GP, Hu Y, Le Leu RK, Nyskohus L. Dietary fibre and colorectal cancer: a model for environment–gene interactions. *Mol Nutr Food Res* 2005;49:571-84.
5. Olmo N, Turnay J, Pérez-Ramos P, Lecona E, Barrasa JI, López de Silanes I, Lizarbe MA. In vitro models for the study of the effect of butyrate on human colon adenocarcinoma cells. *Toxicol In Vitro* 2007;21:262-70.
6. Yang J, Kawai Y, Hanson RW, Arinze IJ. Sodium butyrate induces transcription from the G alpha(2) gene promoter through multiple Sp1 sites in the promoter and by activating the MEK-ERK signal transduction pathway. *J Biol Chem* 2001;276:25742-52.
7. Shah P, Nankova BB, Parab S, La Gamma EF. Short chain fatty acids induce TH gene expression via ERK-dependent phosphorylation of CREB protein. *Brain Res* 2006;1107:13-23.
8. Zhang Y, Zhou L, Bao YL, Wu Y, Yu CL, Huang YX, Sun Y, Zheng LH, Li YX. Butyrate induces cell apoptosis through activation of JNK MAP kinase pathway in human colon cancer RKO cells. *Chem Biol Interact* 2010;185:174-81.
9. Zuo L, Lu M, Zhou Q, Wei W, Wang Y. Butyrate suppresses proliferation and migration of RKO colon cancer cells through regulating endocan expression by MAPK signaling pathway. *Food Chem Toxicol* 2013;62:892-900.
10. Corfield AP, Myerscough N, Longman R, Sylvester P, Arul S, Pignatelli M. Mucins and mucosal protection in the gastrointestinal tract: new prospects for mucins in the pathology of gastrointestinal disease. *Gut* 2000;47:589-94.
11. Han KS, Deglaire A, Sengupta R, Moughan PJ. Hydrolyzed casein influences intestinal mucin gene expression in the rat. *J Agric Food Chem* 2008;56:5572-6.
12. Allen A, Hutton DA, Pearson JP. The MUC2 gene product: a human intestinal mucin. *Int J Biochem Cell Biol* 1998;30:797-801.
13. Gaudier E, Jarry A, Blottière HM, de Coppet P, Buisine MP, Aubert JP, Laboisse C, Cherbut C, Hoebler C. Butyrate specifically modulates MUC gene expression in intestinal epithelial goblet cells deprived of glucose. *Am J Physiol Gastrointest Liver Physiol* 2004;287:G1168-74.
14. Trompette A, Blanchard C, Zoghbi S, Bara J, Claustre J, Jourdan G, Chayvialle JA, Plaisancé P. The DHE cell line as a model for studying rat gastro-intestinal mucin expression: effects of dexamethasone. *Eur J Cell Biol* 2004;83:347-58.
15. Delcenserie V, Martel D, Lamoureux M, Amiot J, Boutin Y, Roy D. Immunomodulatory effects of probiotics in the intestinal tract. *Curr Issues Mol Biol* 2008;10:37-54.
16. Ouwehand AC, Salminen S. In vitro adhesion assays for probiotics and their in vivo relevance: a review. *Microb Ecol Health Dis* 2003;15:175-84.
17. Valeriano VD, Parungao-Balolong MM, Kang DK. In vitro evaluation of the mucin-adhesion ability and probiotic potential of *Lactobacillus mucosae* LM1. *J Appl Microbiol* 2014;117:485-97.
18. Bucki R, Namiot DB, Namiot Z, Savage PB, Janmey PA. Salivary mucins inhibit antibacterial activity of the cathelicidin-derived LL-37 peptide but not the cationic steroid CSA-13. *J Antimicrob Chemother* 2008;62:329-35.
19. Kim YS, Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and progress. *Curr Gastroenterol Rep* 2010;12:319-30.
20. Kober OI, Ahl D, Pin C, Holm L, Carding SR, Juge N. gammadelta T-cell-deficient mice show alterations in mucin expression, glycosylation, and goblet cells but maintain an intact mucus layer. *Am J Physiol Gastrointest Liver Physiol* 2014;306:G582-93.
21. Louis P, Scott KP, Duncan SH, Flint HJ. Understanding the effects of diet on bacterial metabolism in the large intestine. *J Appl Microbiol* 2007;102:1197-208.
22. Pryde SE, Duncan SH, Hold GL, Stewart CS, Flint HJ. The microbiology of butyrate formation in the human colon. *FEMS Microbiol Lett* 2002;217:133-9.
23. Gaudier E, Rival M, Buisine MP, Robineau I, Hoebler C. Butyrate enemas upregulate Muc genes expression but decrease adherent mucus thickness in mice colon. *Physiol Res* 2009;58:111-9.
24. Hatayama H, Iwashita J, Kuwajima A, Abe T. The short chain fatty acid, butyrate, stimulates MUC2 mucin production in the human colon cancer cell line, LS174T. *Biochem Biophys Res Commun* 2007;356:599-603.
25. Barcelo A, Claustre J, Moro F, Chayvialle JA, Cuber JC, Plaisancé P. Mucin secretion is modulated by luminal factors in the isolated vascularly perfused rat colon. *Gut* 2000;46:218-24.
26. Carraway KL, Ramsauer VP, Haq B, Carothers Carraway CA. Cell signaling through membrane mucins. *Bioessays* 2003;25:66-71.
27. Rangel JM, Sparling PH, Crowe C, Griffin PM, Swerdlow DL. Epidemiology of *Escherichia coli* O157:H7 outbreaks, United States, 1982-2002. *Emerg Infect Dis* 2005;11:603-9.
28. Deplancke B, Gaskins HR. Microbial modulation of innate defense: goblet cells and the intestinal mucus layer. *Am J Clin Nutr* 2001;73:1131S-1141S.
29. Mack DR, Ahrne S, Hyde L, Wei S, Hollingsworth MA. Extracellular MUC3 mucin secretion follows adherence of *Lactobacillus* strains to intestinal epithelial cells in vitro. *Gut* 2003;52:827-33.
30. Fujiwara S, Hashiba H, Hirota T, Forstner JF. Proteinaceous factor(s) in culture supernatant fluids of bifidobacteria which prevents the binding of enterotoxigenic *Escherichia coli* to gangliotetraosylceramide. *Appl Environ Microbiol* 1997;63:506-12.
31. Mattar AF, Teitelbaum DH, Drongowski RA, Yongyi F, Harmon CM, Coran AG. Probiotics up-regulate MUC-2 mucin gene expression in a Caco-2 cell-culture model. *Pediatr Surg Int* 2002;18:586-90.
32. Adjei AA. Blocking oncogenic Ras signaling for cancer therapy. *J Natl Cancer Inst* 2001;93:1062-74.
33. Wu KL, Huang EY, Jhu EW, Huang YH, Su WH, Chuang PC, Yang KD. Overexpression of galectin-3 enhances migration of colon cancer cells related to activation of the K-Ras-Raf-Erk1/2 pathway. *J Gastroenterol* 2013;48:350-9.
34. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: a family of protein kinases with diverse biological functions. *Microbiol Mol Biol Rev* 2004;68:320-44.
35. Holz MK, Ballif BA, Gygi SP, Blenis J. mTOR and S6K1 mediate assembly of the translation preinitiation complex through dynamic protein interchange and ordered phosphorylation events. *Cell* 2005;123:569-80.
36. Reber L, Vermeulen L, Haegeman G, Frossard N. Ser276 phosphorylation of NF- $\kappa$ B p65 by MSK1 controls SCF expression in inflammation. *PLoS One* 2009;4:e4393.
37. Gancz D, Lusthaus M, Fishelson Z. A role for the NF-kappaB pathway in cell protection from complement-dependent cytotoxicity. *J Immunol* 2012;189:860-6.

38. Daniel P, Filiz G, Brown DV, Hollande F, Gonzales M, D'Abaco G, Papalexis N, Phillips WA, Malaterre J, Ramsay RG, Mantamadiotis T. Selective CREB-dependent cyclin expression mediated by the PI3K and MAPK pathways supports glioma cell proliferation. *Oncogenesis* 2014;3:e108.
39. Lane DP. Cancer. p53, guardian of the genome. *Nature* 1992;358:15-6.
40. Horn HF, Vousden KH. Coping with stress: multiple ways to activate p53. *Oncogene* 2007;26:1306-16.
41. Williams EA, Coxhead JM, Mathers JC. Anti-cancer effects of butyrate: use of micro-array technology to investigate mechanisms. *Proc Nutr Soc* 2003;62:107-15.
42. Wang HG, Huang XD, Shen P, Li LR, Xue HT, Ji GZ. Anticancer effects of sodium butyrate on hepatocellular carcinoma cells in vitro. *Int J Mol Med* 2013;31:967-74.
43. Perrais M, Pigny P, Copin MC, Aubert JP, Van Seuningem I. Induction of MUC2 and MUC5AC mucins by factors of the epidermal growth factor (EGF) family is mediated by EGF receptor/Ras/Raf/extracellular signal-regulated kinase cascade and Sp1. *J Biol Chem* 2002;277:32258-67.